Severe atypical skin disease in two patients with CLL/SLL after BTKi treatment - a case report and literature review

Severe atypical skin disease in two patients with CLL/SLL after BTKi treatment - a case report and literature review

Dermatological adverse events (AEs) are generally mild during therapy with Bruton’s tyrosine kinase inhibitor (BTKi), and it is often unnecessary to adjust the BTKi dosage or discontinue treatment. However, in this study, we present the cases of two patients diagnosed with chronic lymphocytic leukem...

Full description

Saved in:
Bibliographic Details
Main Authors: Jingxin Zhou, Wentong Ma, Na Hu, Yuhan Ma, Huayuan Zhu, Ling Gao
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-12-01
Series:Frontiers in Oncology
Subjects:
adverse reaction
CLL/SLL
atypical skin lesion
BTK inhibitor
case report
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1467891/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items